• Explore /
  • Poster
  • / A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

Abstract Poster

Authors

null

Alexander I. Spira

Virginia Cancer Specialists and NEXT Oncology, Fairfax, VA

Alexander I. Spira , Elizabeth Katherine Lee , Roisin Eilish O'Cearbhaill , Patricia LoRusso , Gerald Steven Falchook , Manish R. Patel , Debra L. Richardson , Nicole Covino , Wei Lu , Priya Marreddy , Daphne L. Farrington , Jennifer J. Wheler , Eric Daniel Slosberg , Vivek Subbiah , Funda Meric-Bernstam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Chemotherapy and Antibody-Drug Conjugates

Clinical Trial Registration Number

NCT06234423

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS3166)

DOI

10.1200/JCO.2024.42.16_suppl.TPS3166

Abstract #

TPS3166

Poster Bd #

308a

Abstract Disclosures

Similar Posters

First Author: Kyriakos P. Papadopoulos

First Author: Susanna Varkey Ulahannan

First Author: Judy S. Wang

First Author: Funda Meric-Bernstam